Home  |  Contact

Cellosaurus COLO201-AR (CVCL_4V91)

[Text version]

Cell line name COLO201-AR
Accession CVCL_4V91
Resource Identification Initiative To cite this cell line use: COLO201-AR (RRID:CVCL_4V91)
Comments Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
Sequence variations Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1987 (COLO 201)
Sex of cell Male
Age at sampling 70Y
Category Cancer cell line
Publications

PubMed=21098728; DOI=10.1126/scisignal.2001148
Corcoran R.B., Dias-Santagata D., Bergethon K., Iafrate A.J., Settleman J., Engelman J.A.
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
Sci. Signal. 3:Ra84.1-Ra84.10(2010)

Cross-references
Other Wikidata; Q54814209
Entry history
Entry creation14-Dec-2015
Last entry update20-May-2021
Version number7